ULU-Ging Lo

U-Ging Lo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


U-Ging Lo has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Jer-Tsong Hsieh

    Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390, USA

    3 shared publications
  • Chih-Ho Lai

    Department of Microbiology and Immunology, Graduate Institute of Biomedical Sciences, Chang Gung University

    2 shared publications
  • Ho Lin

    Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan

    2 shared publications
  • Cheng-Fan Lee

    Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

    1 shared publication
  • Cheng-Hsun Chiu

    Molecular Infectious Disease Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan

    1 shared publication
  • Chia-Lin Wu

    Department of Biochemistry, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Department of Neurology, New Taipei Municipal TuCheng Hospital, Chang Gung Memorial Hospital, New Taipei City, Taiwan; Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Brain Research Center, National Tsing Hua University, Hsinchu, Taiwan

    1 shared publication

Latest Publications

  • Open Access

    Bacterial Genotoxin-Coated Nanoparticles for Radiotherapy Sensitization in Prostate Cancer

    by Yu-An Chen, Yi-Ru Lai, Hui-Yu Wu, Yen-Ju Lo, Yu-Fang Chang, Chiu-Lien Hung, Chun-Jung Lin, U-Ging Lo, Ho Lin, Jer-Tsong Hsieh, et al.

    Prostate cancer (PCa) is one of the most commonly diagnosed cancers in men and usually becomes refractory because of recurrence and metastasis. CD44, a transmembrane glycoprotein, serves as a receptor for hyaluronic acid (HA). It has been found to be abundantly expressed in cancer stem cells (CSCs) that often exhibit a radioresistant phenotype. Cytolethal distending toxin (CDT), produced by Campylobacter jejuni, is a tripartite genotoxin composed of CdtA, CdtB, and CdtC subunits. Among the three, CdtB acts as a type I deoxyribonuclease (DNase I), which creates DNA double-strand breaks (DSBs). Nanoparticles loaded with antitumor drugs and specific ligands that recognize cancerous cell receptors are promising methods to overcome the therapeutic challenges. In this study, HA-decorated nanoparticle-encapsulated CdtB (HA-CdtB-NPs) were prepared and their targeted therapeutic activity in radioresistant PCa cells was evaluated. Our results showed that HA-CdtB-NPs sensitized radioresistant PCa cells by enhancing DSB and causing G2/M cell-cycle arrest, without affecting the normal prostate epithelial cells. HA-CdtB-NPs possess maximum target specificity and delivery efficiency of CdtB into the nucleus and enhance the effect of radiation in radioresistant PCa cells. These findings demonstrate that HA-CdtB-NPs exert target specificity accompanied with radiomimetic activity and can be developed as an effective strategy against radioresistant PCa.


  • Open Access

    Antrocin Sensitizes Prostate Cancer Cells to Radiotherapy through Inhibiting PI3K/AKT and MAPK Signaling Pathways

    by Yu-An Chen, David T. W. Tzeng, Yi-Ping Huang, Chun-Jung Lin, U-Ging Lo, Chia-Lin Wu, Ho Lin, Jer-Tsong Hsieh, Chih-Hsin Tang, Chih-Ho Lai

    Radiotherapy is one of the most common treatment options for local or regional advanced prostate cancer (PCa). Importantly, PCa is prone to radioresistance and often develops into malignancies after long-term radiotherapy. Antrocin, a sesquiterpene lactone isolated from Antrodia cinnamomea, possesses pharmacological efficacy against various cancer types; however, its therapeutic potential requires comprehensive exploration, particularly in radioresistant PCa cells. In this study, we emphasized the effects of antrocin on radioresistant PCa cells and addressed the molecular mechanism underlying the radiosensitization induced by antrocin. Our results showed that a combination treatment with antrocin and ionizing radiation (IR) synergistically inhibited cell proliferation and induced apoptosis in radioresistant PCa cells. We further demonstrated that antrocin downregulated PI3K/AKT and MAPK signaling pathways as well as suppressed type 1 insulin-like growth factor 1 receptor (IGF-1R)-mediated induction of β-catenin to regulate cell cycle and apoptosis. Using xenograft mouse models, we showed that antrocin effectively enhanced radiotherapy in PCa. Our study demonstrates that antrocin sensitizes PCa to radiation through constitutive suppression of IGF-1R downstream signaling, revealing that it can be developed as a potent therapeutic agent to overcome radioresistant PCa.


  • Open Access

    The Role and Mechanism of Epithelial-to-Mesenchymal Transition in Prostate Cancer Progression

    by U-Ging Lo, Cheng-Fan Lee, Ming-Shyue Lee, Jer-Tsong Hsieh

    In prostate cancer (PCa), similar to many other cancers, distant organ metastasis symbolizes the beginning of the end disease, which eventually leads to cancer death. Many mechanisms have been identified in this process that can be rationalized into targeted therapy. Among them, epithelial-to-mesenchymal transition (EMT) is originally characterized as a critical step for cell trans-differentiation during embryo development and now recognized in promoting cancer cells invasiveness because of high mobility and migratory abilities of mesenchymal cells once converted from carcinoma cells. Nevertheless, the underlying pathways leading to EMT appear to be very diverse in different cancer types, which certainly represent a challenge for developing effective intervention. In this article, we have carefully reviewed the key factors involved in EMT of PCa with clinical correlation in hope to facilitate the development of new therapeutic strategy that is expected to reduce the disease mortality.